Fox Run Management’s Praxis Precision Medicines PRAX Stock Holding History

Fox Run Management’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,393	Closed	-$385K	–	1222
2026 Q1	$385K	Buy	+1,393	New	+$431K	0.07%	545
2025 Q1	–	Sell	-3,195	Closed	-$246K	–	1158
2024 Q4	$246K	Buy	+3,195	New	+$231K	0.04%	703

Other funds holding PRAX

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Fox Run Management's PRAX Position: Q2 2026 in Review

Fox Run Management sold out of Praxis Precision Medicines (PRAX) in Q2 2026, closing a stake of 1,393 shares — an estimated $385K sold.

Fox Run Management first reported a position in PRAX in Q4 2024 and held it in 2 quarters. The position peaked at $385K in Q1 2026. 310 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

Fox Run Management reported no remaining Praxis Precision Medicines position as of Q2 2026 after selling out during the quarter.
Fox Run Management sold 1,393 Praxis Precision Medicines shares in Q2 2026, an estimated $385K.
Fox Run Management first reported a position in Praxis Precision Medicines in Q4 2024 and held it in 2 quarters.
Fox Run Management's Praxis Precision Medicines position peaked at $385K in Q1 2026.
310 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.